{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T06:30:21Z","timestamp":1787725821187,"version":"build-2784847793"},"reference-count":65,"publisher":"Springer Science and Business Media LLC","issue":"25","license":[{"start":{"date-parts":[[2019,3,11]],"date-time":"2019-03-11T00:00:00Z","timestamp":1552262400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Oncogene"],"published-print":{"date-parts":[[2019,6]]},"DOI":"10.1038\/s41388-019-0774-x","type":"journal-article","created":{"date-parts":[[2019,3,11]],"date-time":"2019-03-11T12:02:44Z","timestamp":1552305764000},"page":"5038-5049","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Oncogenic and osteolytic functions of histone demethylase NO66 in castration-resistant prostate cancer"],"prefix":"10.1038","volume":"38","author":[{"given":"Krishna M.","family":"Sinha","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rozita","family":"Bagheri-Yarmand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9215-3634","authenticated-orcid":false,"given":"Sharmistha","family":"Lahiri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Amra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasmeen","family":"Rizvi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinhai","family":"Wan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nora","family":"Navone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bulent","family":"Ozpolat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Logothetis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert F.","family":"Gagel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johnny","family":"Huard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,3,11]]},"reference":[{"key":"774_CR1","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1038\/nrc1528","volume":"5","author":"CJ Logothetis","year":"2005","unstructured":"Logothetis CJ, Lin SH. Osteoblasts in prostate cancer metastasis to bone. Nat Rev Cancer. 2005;5:21\u20138.","journal-title":"Nat Rev Cancer"},{"key":"774_CR2","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.1158\/1078-0432.CCR-07-4603","volume":"14","author":"CJ Logothetis","year":"2008","unstructured":"Logothetis CJ, Navone NM, Lin SH. Understanding the biology of bone metastases: key to the effective treatment of prostate cancer. Clin Cancer Res. 2008;14:1599\u2013602.","journal-title":"Clin Cancer Res"},{"key":"774_CR3","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1038\/onc.2009.389","volume":"29","author":"J Akech","year":"2010","unstructured":"Akech J, Wixted JJ, Bedard K, van der Deen M, Hussain S, Guise TA, et al. Runx2 association with progression of prostate cancer in patients: mechanisms mediating bone osteolysis and osteoblastic metastatic lesions. Oncogene. 2010;29:811\u201321.","journal-title":"Oncogene"},{"key":"774_CR4","doi-asserted-by":"publisher","DOI":"10.1186\/1476-4598-11-52","volume":"11","author":"F Crea","year":"2012","unstructured":"Crea F, Sun L, Mai A, Chiang YT, Farrar WL, Danesi R, et al. The emerging role of histone lysine demethylases in prostate cancer. Mol Cancer. 2012;11:52.","journal-title":"Mol Cancer"},{"key":"774_CR5","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1002\/pros.21038","volume":"70","author":"J Ellinger","year":"2010","unstructured":"Ellinger J, Kahl P, von der Gathen J, Rogenhofer S, Heukamp LC, Gutgemann I, et al. Global levels of histone modifications predict prostate cancer recurrence. Prostate. 2010;70:61\u20139.","journal-title":"Prostate"},{"key":"774_CR6","doi-asserted-by":"publisher","first-page":"1465","DOI":"10.1126\/science.1227604","volume":"338","author":"K Xu","year":"2012","unstructured":"Xu K, Wu ZJ, Groner AC, He HH, Cai C, Lis RT, et al. EZH2 oncogenic activity in castration-resistant prostate cancer cells is Polycomb-independent. Science. 2012;338:1465\u20139.","journal-title":"Science"},{"key":"774_CR7","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1007\/s13238-013-2093-2","volume":"4","author":"YA Yang","year":"2013","unstructured":"Yang YA, Yu J. EZH2, an epigenetic driver of prostate cancer. Protein & Cell. 2013;4:331\u201341.","journal-title":"Protein & Cell"},{"key":"774_CR8","doi-asserted-by":"publisher","first-page":"10657","DOI":"10.1158\/0008-5472.CAN-07-2498","volume":"67","author":"J Yu","year":"2007","unstructured":"Yu J, Yu J, Rhodes DR, Tomlins SA, Cao X, Chen G, et al. A polycomb repression signature in metastatic prostate cancer predicts cancer outcome. Cancer Res. 2007;67:10657\u201363.","journal-title":"Cancer Res"},{"key":"774_CR9","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1038\/nm.3830","volume":"21","author":"R Malik","year":"2015","unstructured":"Malik R, Khan AP, Asangani IA, Cieslik M, Prensner JR, Wang X, et al. Targeting the MLL complex in castration-resistant prostate cancer. Nat Med. 2015;21:344\u201352.","journal-title":"Nat Med"},{"key":"774_CR10","doi-asserted-by":"publisher","first-page":"1681","DOI":"10.1002\/pros.20836","volume":"68","author":"B Saha","year":"2008","unstructured":"Saha B, Kaur P, Tsao-Wei D, Naritoku WY, Groshen S, Datar RH, et al. Unmethylated E-cadherin gene expression is significantly associated with metastatic human prostate cancer cells in bone. Prostate. 2008;68:1681\u20138.","journal-title":"Prostate"},{"key":"774_CR11","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1359\/jbmr.2001.16.3.487","volume":"16","author":"H Tamada","year":"2001","unstructured":"Tamada H, Kitazawa R, Gohji K, Kitazawa S. Epigenetic regulation of human bone morphogenetic protein 6 gene expression in prostate cancer. J Bone Miner Res. 2001;16:487\u201396.","journal-title":"J Bone Miner Res"},{"key":"774_CR12","doi-asserted-by":"publisher","first-page":"2697","DOI":"10.1172\/JCI33637C1","volume":"118","author":"ZG Li","year":"2008","unstructured":"Li ZG, Mathew P, Yang J, Starbuck MW, Zurita AJ, Liu J, et al. Androgen receptor-negative human prostate cancer cells induce osteogenesis in mice through FGF9-mediated mechanisms. J Clin Invest. 2008;118:2697\u2013710.","journal-title":"J Clin Invest"},{"key":"774_CR13","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1158\/1078-0432.CCR-11-2521","volume":"18","author":"X Wan","year":"2012","unstructured":"Wan X, Liu J, Lu JF, Tzelepi V, Yang J, Starbuck MW, et al. Activation of beta-catenin signaling in androgen receptor-negative prostate cancer cells. Clin Cancer Res. 2012;18:726\u201336.","journal-title":"Clin Cancer Res"},{"key":"774_CR14","doi-asserted-by":"publisher","first-page":"5194","DOI":"10.1158\/0008-5472.CAN-10-4374","volume":"71","author":"YC Lee","year":"2011","unstructured":"Lee YC, Cheng CJ, Bilen MA, Lu JF, Satcher RL, Yu-Lee LY, et al. BMP4 promotes prostate tumor growth in bone through osteogenesis. Cancer Res. 2011;71:5194\u2013203.","journal-title":"Cancer Res"},{"key":"774_CR15","doi-asserted-by":"publisher","first-page":"5747","DOI":"10.1158\/0008-5472.CAN-07-0478","volume":"67","author":"XH Liu","year":"2007","unstructured":"Liu XH, Kirschenbaum A, Yao S, Liu G, Aaronson SA, Levine AC. Androgen-induced Wnt signaling in preosteoblasts promotes the growth of MDA-PCa-2b human prostate cancer cells. Cancer Res. 2007;67:5747\u201353.","journal-title":"Cancer Res"},{"key":"774_CR16","doi-asserted-by":"publisher","first-page":"7976","DOI":"10.1158\/0008-5472.CAN-04-4076","volume":"65","author":"HJ Zhou","year":"2005","unstructured":"Zhou HJ, Yan J, Luo W, Ayala G, Lin SH, Erdem H, et al. SRC-3 is required for prostate cancer cell proliferation and survival. Cancer Res. 2005;65:7976\u201383.","journal-title":"Cancer Res"},{"key":"774_CR17","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.canlet.2005.06.004","volume":"237","author":"M Verras","year":"2006","unstructured":"Verras M, Sun Z. Roles and regulation of Wnt signaling and beta-catenin in prostate cancer. Cancer Lett. 2006;237:22\u201332.","journal-title":"Cancer Lett"},{"key":"774_CR18","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/j.bone.2005.07.015","volume":"38","author":"BT Feeley","year":"2006","unstructured":"Feeley BT, Krenek L, Liu N, Hsu WK, Gamradt SC, Schwarz EM, et al. Overexpression of noggin inhibits BMP-mediated growth of osteolytic prostate cancer lesions. Bone. 2006;38:154\u201366.","journal-title":"Bone"},{"key":"774_CR19","doi-asserted-by":"publisher","first-page":"2189","DOI":"10.1359\/JBMR.050802","volume":"20","author":"BT Feeley","year":"2005","unstructured":"Feeley BT, Gamradt SC, Hsu WK, Liu N, Krenek L, Robbins P, et al. Influence of BMPs on the formation of osteoblastic lesions in metastatic prostate cancer. J Bone Miner Res. 2005;20:2189\u201399.","journal-title":"J Bone Miner Res"},{"key":"774_CR20","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1038\/emboj.2009.332","volume":"29","author":"KM Sinha","year":"2010","unstructured":"Sinha KM, Yasuda H, Coombes MM, Dent SY, de Crombrugghe B. Regulation of the osteoblast-specific transcription factor Osterix by NO66, a Jumonji family histone demethylase. EMBO J. 2010;29:68\u201379.","journal-title":"EMBO J"},{"key":"774_CR21","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1002\/jcb.24439","volume":"114","author":"KM Sinha","year":"2013","unstructured":"Sinha KM, Zhou X. Genetic and molecular control of osterix in skeletal formation. J Cell Biochem. 2013;114:975\u201384.","journal-title":"J Cell Biochem"},{"key":"774_CR22","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1002\/jbmr.2103","volume":"29","author":"KM Sinha","year":"2014","unstructured":"Sinha KM, Yasuda H, Zhou X, deCrombrugghe B. Osterix and NO66 histone demethylase control the chromatin of Osterix target genes during osteoblast differentiation. J Bone Miner Res. 2014;29:855\u201365.","journal-title":"J Bone Miner Res"},{"key":"774_CR23","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1038\/nchembio.1093","volume":"8","author":"W Ge","year":"2012","unstructured":"Ge W, Wolf A, Feng T, Ho CH, Sekirnik R, Zayer A, et al. Oxygenase-catalyzed ribosome hydroxylation occurs in prokaryotes and humans. Nat Chem Biol. 2012;8:960\u20132.","journal-title":"Nat Chem Biol"},{"key":"774_CR24","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1038\/nsmb.2449","volume":"19","author":"GL Brien","year":"2012","unstructured":"Brien GL, Gambero G, O\u2019Connell DJ, Jerman E, Turner SA, Egan CM, et al. Polycomb PHF19 binds H3K36me3 and recruits PRC2 and demethylase NO66 to embryonic stem cell genes during differentiation. Nat Struct Mol Biol. 2012;19:1273\u201381.","journal-title":"Nat Struct Mol Biol"},{"key":"774_CR25","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1080\/15592294.2015.1103578","volume":"10","author":"AS Pires-Luis","year":"2015","unstructured":"Pires-Luis AS, Vieira-Coimbra M, Vieira FQ, Costa-Pinheiro P, Silva-Santos R, Dias PC, et al. Expression of histone methyltransferases as novel biomarkers for renal cell tumor diagnosis and prognostication. Epigenetics. 2015;10:1033\u201343.","journal-title":"Epigenetics"},{"key":"774_CR26","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1245\/s10434-016-5395-9","volume":"24","author":"Y Nishizawa","year":"2017","unstructured":"Nishizawa Y, Nishida N, Konno M, Kawamoto K, Asai A, Koseki J, et al. Clinical significance of histone demethylase NO66 in invasive colorectal cancer. Ann Surg Oncol. 2017;24:841\u20139.","journal-title":"Ann Surg Oncol"},{"key":"774_CR27","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1038\/onc.2015.91","volume":"35","author":"C Ge","year":"2016","unstructured":"Ge C, Zhao G, Li Y, Li H, Zhao X, Pannone G, et al. Role of Runx2 phosphorylation in prostate cancer and association with metastatic disease. Oncogene. 2016;35:366\u201376.","journal-title":"Oncogene"},{"key":"774_CR28","doi-asserted-by":"publisher","first-page":"5613","DOI":"10.1158\/1078-0432.CCR-13-1151","volume":"19","author":"M Yepuru","year":"2013","unstructured":"Yepuru M, Wu Z, Kulkarni A, Yin F, Barrett CM, Kim J, et al. Steroidogenic enzyme AKR1C3 is a novel androgen receptor-selective coactivator that promotes prostate cancer growth. Clin Cancer Res. 2013;19:5613\u201325.","journal-title":"Clin Cancer Res"},{"key":"774_CR29","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/j.jsbmb.2013.05.012","volume":"137","author":"AO Adeniji","year":"2013","unstructured":"Adeniji AO, Chen M, Penning TM. AKR1C3 as a target in castrate resistant prostate cancer. J Steroid Biochem Mol Biol. 2013;137:136\u201349.","journal-title":"J Steroid Biochem Mol Biol"},{"key":"774_CR30","doi-asserted-by":"publisher","first-page":"119","DOI":"10.3389\/fphar.2017.00119","volume":"8","author":"CM Zeng","year":"2017","unstructured":"Zeng CM, Chang LL, Ying MD, Cao J, He QJ, Zhu H, et al. Aldo-keto reductase AKR1C1-AKR1C4: functions, regulation, and intervention for anti-cancer therapy. Front Pharmacol. 2017;8:119.","journal-title":"Front Pharmacol"},{"key":"774_CR31","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.acthis.2017.11.002","volume":"120","author":"G Liang","year":"2018","unstructured":"Liang G, Fang X, Yang Y, Song Y. Silencing of CEMIP suppresses Wnt\/beta-catenin\/Snail signaling transduction and inhibits EMT program of colorectal cancer cells. Acta Histochem. 2018;120:56\u201363.","journal-title":"Acta Histochem"},{"key":"774_CR32","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1139\/bcb-2017-0151","volume":"96","author":"G Liang","year":"2017","unstructured":"Liang G, Fang X, Yang Y, Song Y. Knockdown of CEMIP suppresses proliferation and induces apoptosis in colorectal cancer cells: downregulation of GRP78 and attenuation of unfolded protein response. Biochem Cell Biol. 2017;96:332\u201341.","journal-title":"Biochem Cell Biol"},{"key":"774_CR33","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1593\/neo.07976","volume":"10","author":"LA Begley","year":"2008","unstructured":"Begley LA, Kasina S, Mehra R, Adsule S, Admon AJ, Lonigro RJ, et al. CXCL5 promotes prostate cancer progression. Neoplasia . 2008;10:244\u201354.","journal-title":"Neoplasia"},{"key":"774_CR34","doi-asserted-by":"publisher","first-page":"747","DOI":"10.3892\/ijmm.2013.1472","volume":"32","author":"K Ji","year":"2013","unstructured":"Ji K, Ye L, Mason MD, Jiang WG. The Kiss-1\/Kiss-1R complex as a negative regulator of cell motility and cancer metastasis (Review). Int J Mol Med. 2013;32:747\u201354.","journal-title":"Int J Mol Med"},{"key":"774_CR35","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.1016\/j.ajpath.2011.11.020","volume":"180","author":"H Wang","year":"2012","unstructured":"Wang H, Jones J, Turner T, He QP, Hardy S, Grizzle WE, et al. Clinical and biological significance of KISS1 expression in prostate cancer. Am J Pathol. 2012;180:1170\u20138.","journal-title":"Am J Pathol"},{"key":"774_CR36","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1111\/j.1365-2567.2011.03513.x","volume":"135","author":"MH Park","year":"2012","unstructured":"Park MH, Song MJ, Cho MC, Moon DC, Yoon DY, Han SB, et al. Interleukin-32 enhances cytotoxic effect of natural killer cells to cancer cells via activation of death receptor 3. Immunology. 2012;135:63\u201372.","journal-title":"Immunology"},{"key":"774_CR37","doi-asserted-by":"crossref","first-page":"35","DOI":"10.59566\/IJBS.2017.13035","volume":"13","author":"J Rebollo","year":"2017","unstructured":"Rebollo J, Geliebter J, Reyes N. ESM-1 siRNA knockdown decreased migration and expression of CXCL3 in prostate cancer cells. Int J Biomed Sci. 2017;13:35\u201342.","journal-title":"Int J Biomed Sci"},{"key":"774_CR38","doi-asserted-by":"publisher","first-page":"e153","DOI":"10.5301\/jbm.5000184","volume":"31","author":"A Bettin","year":"2016","unstructured":"Bettin A, Reyes I, Reyes N. Gene expression profiling of prostate cancer-associated genes identifies fibromodulin as potential novel biomarker for prostate cancer. Int J Biol Markers. 2016;31:e153\u201362.","journal-title":"Int J Biol Markers"},{"key":"774_CR39","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1080\/1120009X.2016.1277007","volume":"29","author":"E Cacan","year":"2017","unstructured":"Cacan E. Epigenetic regulation of RGS2 (Regulator of G-protein signaling 2) in chemoresistant ovarian cancer cells. J Chemother. 2017;29:173\u20138.","journal-title":"J Chemother"},{"key":"774_CR40","doi-asserted-by":"publisher","first-page":"1521","DOI":"10.1002\/ijc.26138","volume":"130","author":"DW Wolff","year":"2012","unstructured":"Wolff DW, Xie Y, Deng C, Gatalica Z, Yang M, Wang B, et al. Epigenetic repression of regulator of G-protein signaling 2 promotes androgen-independent prostate cancer cell growth. Int J Cancer. 2012;130:1521\u201331.","journal-title":"Int J Cancer"},{"key":"774_CR41","first-page":"8483","volume":"23","author":"RP Chowdry","year":"2016","unstructured":"Chowdry RP, Ledet E, Ranasinghe L, Sartor AO. MLL translocation in two castration-resistant prostate cancer patients. Can J Urol. 2016;23:8483\u20136.","journal-title":"Can J Urol"},{"key":"774_CR42","doi-asserted-by":"publisher","first-page":"3725","DOI":"10.1158\/0008-5472.CAN-12-3468","volume":"73","author":"HJ Jin","year":"2013","unstructured":"Jin HJ, Zhao JC, Ogden I, Bergan RC, Yu J. Androgen receptor-independent function of FoxA1 in prostate cancer metastasis. Cancer Res. 2013;73:3725\u201336.","journal-title":"Cancer Res"},{"key":"774_CR43","doi-asserted-by":"publisher","first-page":"319","DOI":"10.3892\/ol_00000057","volume":"1","author":"O Bragina","year":"2010","unstructured":"Bragina O, Njunkova N, Sergejeva S, Jarvekulg L, Kogerman P. Sonic Hedgehog pathway activity in prostate cancer. Oncol Lett. 2010;1:319\u201325.","journal-title":"Oncol Lett"},{"key":"774_CR44","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1002\/mc.22177","volume":"54","author":"X Chen","year":"2015","unstructured":"Chen X, Cheng H, Pan T, Liu Y, Su Y, Ren C, et al. mTOR regulate EMT through RhoA and Rac1 pathway in prostate cancer. Mol Carcinog. 2015;54:1086\u201395.","journal-title":"Mol Carcinog"},{"key":"774_CR45","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1158\/0008-5472.CAN-16-0497","volume":"77","author":"S Nandana","year":"2017","unstructured":"Nandana S, Tripathi M, Duan P, Chu CY, Mishra R, Liu C, et al. Bone metastasis of prostate cancer can be therapeutically targeted at the TBX2-WNT signaling axis. Cancer Res. 2017;77:1331\u201344.","journal-title":"Cancer Res"},{"key":"774_CR46","first-page":"101","volume":"1","author":"JL Sottnik","year":"2012","unstructured":"Sottnik JL, Hall CL, Zhang J, Keller ET. Wnt and Wnt inhibitors in bone metastasis. Bone Rep. 2012;1:101.","journal-title":"Bone Rep"},{"key":"774_CR47","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1002\/cncr.20518","volume":"101","author":"G Chen","year":"2004","unstructured":"Chen G, Shukeir N, Potti A, Sircar K, Aprikian A, Goltzman D, et al. Upregulation of Wnt-1 and beta-catenin production in patients with advanced metastatic prostate carcinoma: potential pathogenetic and prognostic implications. Cancer. 2004;101:1345\u201356.","journal-title":"Cancer"},{"key":"774_CR48","doi-asserted-by":"publisher","first-page":"9303","DOI":"10.1007\/s13277-015-3676-8","volume":"36","author":"G Xiang","year":"2015","unstructured":"Xiang G, Yi Y, Weiwei H, Weiming W. TGIF1 promoted the growth and migration of cancer cells in nonsmall cell lung cancer. Tumour Biol. 2015;36:9303\u201310.","journal-title":"Tumour Biol"},{"key":"774_CR49","doi-asserted-by":"publisher","first-page":"1888","DOI":"10.1182\/blood-2011-11-393348","volume":"119","author":"S D\u2019Souza","year":"2012","unstructured":"D\u2019Souza S, Kurihara N, Shiozawa Y, Joseph J, Taichman R, Galson DL, et al. Annexin II interactions with the annexin II receptor enhance multiple myeloma cell adhesion and growth in the bone marrow microenvironment. Blood. 2012;119:1888\u201396.","journal-title":"Blood"},{"key":"774_CR50","doi-asserted-by":"crossref","first-page":"3904","DOI":"10.18632\/oncotarget.2880","volume":"6","author":"S Cai","year":"2015","unstructured":"Cai S, Chen R, Li X, Cai Y, Ye Z, Li S, et al. Downregulation of microRNA-23a suppresses prostate cancer metastasis by targeting the PAK6-LIMK1 signaling pathway. Oncotarget. 2015;6:3904\u201317.","journal-title":"Oncotarget"},{"key":"774_CR51","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1158\/2159-8290.CD-12-0177","volume":"2","author":"Z Wang","year":"2012","unstructured":"Wang Z, Wei W, Sarkar FH. miR-23a, a critical regulator of \u201cmigR\u201cation and metastasis in colorectal cancer. Cancer Discov. 2012;2:489\u201391.","journal-title":"Cancer Discov"},{"key":"774_CR52","doi-asserted-by":"publisher","first-page":"223","DOI":"10.3233\/CBM-160634","volume":"17","author":"B Yang","year":"2016","unstructured":"Yang B, Liu Z, Ning H, Zhang K, Pan D, Ding K, et al. MicroRNA-21 in peripheral blood mononuclear cells as a novel biomarker in the diagnosis and prognosis of prostate cancer. Cancer Biomark. 2016;17:223\u201330.","journal-title":"Cancer Biomark"},{"key":"774_CR53","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0051655","volume":"7","author":"S Sheth","year":"2012","unstructured":"Sheth S, Jajoo S, Kaur T, Mukherjea D, Sheehan K, Rybak LP, et al. Resveratrol reduces prostate cancer growth and metastasis by inhibiting the Akt\/MicroRNA-21 pathway. PLoS ONE. 2012;7:e51655.","journal-title":"PLoS ONE"},{"key":"774_CR54","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-018-0869-2","volume":"9","author":"S Wang","year":"2018","unstructured":"Wang S, Ke H, Zhang H, Ma Y, Ao L, Zou L, et al. LncRNA MIR100HG promotes cell proliferation in triple-negative breast cancer through triplex formation with p27 loci. Cell Death Dis. 2018;9:805.","journal-title":"Cell Death Dis"},{"key":"774_CR55","doi-asserted-by":"publisher","first-page":"3185","DOI":"10.3892\/or.2016.4715","volume":"35","author":"C Shang","year":"2016","unstructured":"Shang C, Zhu W, Liu T, Wang W, Huang G, Huang J, et al. Characterization of long non-coding RNA expression profiles in lymph node metastasis of early-stage cervical cancer. Oncol Rep. 2016;35:3185\u201397.","journal-title":"Oncol Rep"},{"key":"774_CR56","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1158\/1535-7163.MCT-06-0659","volume":"6","author":"C Suzuki","year":"2007","unstructured":"Suzuki C, Takahashi K, Hayama S, Ishikawa N, Kato T, Ito T, et al. Identification of Myc-associated protein with JmjC domain as a novel therapeutic target oncogene for lung cancer. Mol Cancer Ther. 2007;6:542\u201351.","journal-title":"Mol Cancer Ther"},{"key":"774_CR57","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1530\/ERC-13-0375","volume":"21","author":"FQ Vieira","year":"2014","unstructured":"Vieira FQ, Costa-Pinheiro P, Ramalho-Carvalho J, Pereira A, Menezes FD, Antunes L, et al. Deregulated expression of selected histone methylases and demethylases in prostate carcinoma. Endocr Relat Cancer. 2014;21:51\u201361.","journal-title":"Endocr Relat Cancer"},{"key":"774_CR58","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1172\/JCI78132","volume":"126","author":"TD Kim","year":"2016","unstructured":"Kim TD, Jin F, Shin S, Oh S, Lightfoot SA, Grande JP, et al. Histone demethylase JMJD2A drives prostate tumorigenesis through transcription factor ETV1. J Clin Invest. 2016;126:706\u201320.","journal-title":"J Clin Invest"},{"key":"774_CR59","doi-asserted-by":"publisher","first-page":"2815","DOI":"10.1158\/0008-5472.CAN-05-4000","volume":"66","author":"M Stanbrough","year":"2006","unstructured":"Stanbrough M, Bubley GJ, Ross K, Golub TR, Rubin MA, Penning TM, et al. Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer. Cancer Res. 2006;66:2815\u201325.","journal-title":"Cancer Res"},{"key":"774_CR60","doi-asserted-by":"publisher","first-page":"4752","DOI":"10.1158\/0008-5472.CAN-15-3393","volume":"76","author":"M Morrison Joly","year":"2016","unstructured":"Morrison Joly M, Hicks DJ, Jones B, Sanchez V, Estrada MV, Young C, et al. Rictor\/mTORC2 drives progression and therapeutic resistance of HER2-Amplified breast cancers. Cancer Res. 2016;76:4752\u201364.","journal-title":"Cancer Res"},{"key":"774_CR61","first-page":"225","volume":"192","author":"A Ortiz","year":"2012","unstructured":"Ortiz A, Lin SH. Osteolytic and osteoblastic bone metastases: two extremes of the same spectrum? Recent Results Cancer Res Fortschr der Krebsforsch Progres dans Les Rech sur Le Cancer. 2012;192:225\u201333.","journal-title":"Recent Results Cancer Res Fortschr der Krebsforsch Progres dans Les Rech sur Le Cancer"},{"key":"774_CR62","doi-asserted-by":"publisher","first-page":"16430","DOI":"10.1074\/jbc.M112.446849","volume":"288","author":"Y Tao","year":"2013","unstructured":"Tao Y, Wu M, Zhou X, Yin W, Hu B, de Crombrugghe B, et al. Structural insights into histone demethylase NO66 in interaction with osteoblast-specific transcription factor osterix and gene repression. J Biol Chem. 2013;288:16430\u20137.","journal-title":"J Biol Chem"},{"key":"774_CR63","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1038\/nature13263","volume":"510","author":"R Chowdhury","year":"2014","unstructured":"Chowdhury R, Sekirnik R, Brissett NC, Krojer T, Ho CH, Ng SS, et al. Ribosomal oxygenases are structurally conserved from prokaryotes to humans. Nature. 2014;510:422\u20136.","journal-title":"Nature"},{"key":"774_CR64","doi-asserted-by":"publisher","first-page":"29403","DOI":"10.1074\/jbc.M103129200","volume":"276","author":"R Bagheri-Yarmand","year":"2001","unstructured":"Bagheri-Yarmand R, Mandal M, Taludker AH, Wang RA, Vadlamudi RK, Kung HJ, et al. Etk\/Bmx tyrosine kinase activates Pak1 and regulates tumorigenicity of breast cancer cells. J Biol Chem. 2001;276:29403\u20139.","journal-title":"J Biol Chem"},{"key":"774_CR65","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1126\/science.1250255","volume":"346","author":"JP Theurillat","year":"2014","unstructured":"Theurillat JP, Udeshi ND, Errington WJ, Svinkina T, Baca SC, Pop M, et al. Prostate cancer. Ubiquitylome analysis identifies dysregulation of effector substrates in SPOP-mutant prostate cancer. Science. 2014;346:85\u20139.","journal-title":"Science"}],"container-title":["Oncogene"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41388-019-0774-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41388-019-0774-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41388-019-0774-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,14]],"date-time":"2023-09-14T11:26:04Z","timestamp":1694690764000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41388-019-0774-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3,11]]},"references-count":65,"journal-issue":{"issue":"25","published-print":{"date-parts":[[2019,6]]}},"alternative-id":["774"],"URL":"https:\/\/doi.org\/10.1038\/s41388-019-0774-x","relation":{},"ISSN":["0950-9232","1476-5594"],"issn-type":[{"value":"0950-9232","type":"print"},{"value":"1476-5594","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,3,11]]},"assertion":[{"value":"19 June 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 December 2018","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 February 2019","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 March 2019","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}